Dipan Karumsi’s Post

We recently released our inaugural KPMG US American Perspectives Survey which explores the economic outlook, spending plans and perspectives of adults nationwide as well as attitudes on the forces shaping their experience in banking, energy, government, automobiles, healthcare and technology.     In #healthcare and #lifesciences, the findings highlight how emerging technologies and innovations such as GLP-1 drugs and #GenAI are reshaping the sector.     For example, according to the findings, only 34% of people do not believe GLP-1s are important to them personally. Additionally, people believe GenAI will improve the consumer experience, but are wary of less human interaction.     Click here for additional insights: https://lnkd.in/eg_6RBsm  

OUT NOW 👉 Medtech Pulse of the industry Learn and enjoy a read on: 1. Restore medtech growth 2. Attract investors during uncertainty 3. Invest for strategic growth 4. Foster innovation ecosystem investment

How can medtech restore its growth trajectory? #Digitalization and #innovation are critical in a complex geopolitical climate with increasingly sophisticated consumers. Read more in the EY Pulse of the Industry report.

Lots of evolution in the Medtech sector with technology enablement's and innovation including GenAi. Check out the 17th edition of EY Pulse on the industry - https://lnkd.in/gcfjfxXu

🛣 Navigating Pharma's Evolution: Challenges and Innovations 🌐💊 In the intricate dance of economic uncertainties and industry-specific challenges, the pharmaceutical sector stands at a pivotal juncture. Recent Forbes Finance Council article explores the hurdles and the innovation imperative. 💡 Key Challenges: 📉 $300B topline erosion from patent expirations. 💼 Cost squeeze as SG&A and R&D spending face stagnation. 🌐 Rising energy, raw material, and labor costs. 🌟 Innovation Imperative: Amid a dynamic landscape, pharma turns to emerging technologies, with Artificial Intelligence (AI) and Machine Learning (ML) at the forefront. These catalysts are reshaping operations, enhancing drug discovery, and revolutionizing clinical trials. 💪 The Path Forward: Cutting costs becomes a strategic move to fuel the innovation engine. However, it's not just about cost-cutting; it's about reimagining the industry in terms of people, processes, and technology to navigate this challenging business cycle successfully. 📖 Read the full Forbes Finance Council article for deep insights into the transformative journey that lies ahead for the pharmaceutical industry. Let's shape the future together! 💬🔬 https://lnkd.in/g8X_xJCH #PharmaInnovation #Leadership #AIinHealthcare #BusinessEvolution #ForbesFinance #HealthcareRevolution #InnovateWithImpact

Exciting news! Our latest sector report, "Next in pharma 2024: Reinventing for returns," is now available. It covers our perspectives on the major trends that will shape pharma’s executive agenda in 2024. Despite numerous breakthroughs in the industry, the value problem persists, and investors are still coming up short. The sector continues to experience under-performance in capital markets relative to the market index. To address this issue, the report dives into five key strategies pharma leaders should consider to compete differently in the years ahead. These include rethinking the innovation strategy, accelerating the use of AI and analytics, lowering costs, using M&A as a catalyst for transformation, and protecting the enterprise. Are you curious about how these strategies can help reinvent the pharma business model? Download and check out the PwC report and let's connect to hear your thoughts! #healthcare #lifesciences #mergersandacquisitions #privateequity #innovation #strategy #transformation #analytics #pharma Glenn Hunzinger Greg Rotz Laura Robinette Zubin Daruwalla Ronald Chopoorian Dr Rana Mehta Jan Schmitz-Huebsch Dr. Walid Tohme Irfan Merali Amit Dixit Ramesh Kannan Sunny Sharma Raj D. Abrar Mir Dr. Amit Varma Asia Healthcare Holdings

The 17th edition of the EY Pulse of the Industry medical technology report is now live!

Thanks for sharing Will Dupre. In line with your findings, I'm regularly discussing the opportunities (and risks) that GenAI will offer to organisations. Accelerating suitable skills development not only for technology and R&D teams, but also the wider organisation, is critical if companies want to remain competitive and leverage the growth and efficiencies that AI can deliver.

While no industry or sector will be untouched by #GenAI, #pharmaceuticals is among the sectors with the greatest immediate opportunities to create value from GenAI, according to research by PwC and Strategy&. In sectors such as retail and corporate banking and insurance - where operating costs are high - efficiency is a commonly cited benefit of GenAI. This contrasts to industries such as pharma and media, where we expect more than 50% of its value to come from new revenue growth opportunities. However, achieving such gains will rely on organisations understanding the strategic implications of GenAI, and making decisions that balance risk and reputation with the right business reward. Find out more here https://pwc.to/3S8X2Ls #HumanLedTechPowered 

Congrats to the DLA Piper #LifeSciences team in producing this inaugural index. My headline takeaways: (i) the UK is one of the least attractive markets for fostering innovation and growth in this sector - we must and should be doing better given our academic pedigree and entrepreneurial spirit; (ii) inorganic growth (38%) only just lags behind organic growth (41%) - M&A and partnerships is definitely becoming more attractive; (iii) regulation, data privacy and cybersecurity are top of mind agenda items with ESG and sustainability slipping down the pecking order (but with mandatory reporting on the horizon for most (and hopefully a more stable macro environment) I expect this to change in our next iteration). Get your copy by following the link below and I would love to hear from contacts (new and old) on your thoughts on the findings and/or what you want to see in the next iteration. #InnovationandGrowth #Dealmaking #Sustainability #ESG #AI #CareDelivery #WeBringTheWorldCloser